Samjin Pharmaceutical announced on Monday that it has entered into a strategic memorandum of understanding (MOU) with Ewha Womans University Medical Center to collaborate on research for central nervous system (CNS) disorder treatments.
This partnership aims to combine the research capabilities of both institutions to develop treatments for various CNS disorders, including migraines. The agreement establishes a framework for ongoing collaboration through shared expertise and operational synergies, building on their joint research and development efforts.
To facilitate successful drug development, Samjin Pharmaceutical and Ewha Womans University Medical Center have established a division of responsibilities based on their respective core competencies.
Samjin Pharmaceutical will spearhead early-stage drug development research, focusing on antibody discovery and engineering, candidate substance optimization, and both in vitro and in vivo preclinical evaluations.
Ewha Womans University Medical Center will contribute its clinical expertise and patient-based research experience to provide insights into disease mechanisms and pathophysiology. The medical center will also offer consultations on clinical efficacy validation and expert opinions.
Of particular note, Professor Song Tae-jin, who was recently appointed director of the Ewha Medical Science Research Institute in March, is a renowned expert in migraine research. His involvement is expected to be instrumental in providing clinical consultations and validating disease mechanisms throughout this collaborative effort.
Furthermore, this agreement opens the door for Samjin Pharmaceutical and Ewha Womans University Medical Center to actively pursue joint research opportunities through government-funded projects and industry-academia collaboration programs.
Lee Soo-min, head of Samjin Pharmaceutical’s research center, expressed optimism about the collaboration, stating that they’re thrilled to partner with Ewha Womans University Medical Center, given their outstanding clinical expertise in CNS disorders, particularly in migraines. The synergy between Samjin Pharmaceutical’s antibody research capabilities and Ewha Womans University Medical Center’s clinical research infrastructure will undoubtedly accelerate the development of groundbreaking treatments.